Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
MSC
T-cell exclusion
immunotherapy
mesenchymal stem cell
prostate cancer
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
14
08
2018
accepted:
17
10
2018
pubmed:
30
11
2018
medline:
16
11
2019
entrez:
30
11
2018
Statut:
ppublish
Résumé
Prostate cancer is characterized by T-cell exclusion, which is consistent with their poor responses to immunotherapy. In addition, T-cells restricted to the adjacent stroma and benign areas are characterized by anergic and immunosuppressive phenotypes. In order for immunotherapies to produce robust anti-tumor responses in prostate cancer, this exclusion barrier and immunosuppressive microenvironment must first be overcome. We have previously identified mesenchymal stem cells (MSCs) in primary and metastatic human prostate cancer tissue. An Opal Multiplex immunofluorescence assay based on CD73, CD90, and CD105 staining was used to identify triple-labeled MSCs in human prostate cancer tissue. T-cell suppression assays and flow cytometry were used to demonstrate the immunosuppressive potential of primary MSCs expanded from human bone marrow and prostate cancer tissue from independent donors. Endogenous MSCs were confirmed to be present at sites of human prostate cancer. These prostate cancer-infiltrating MSCs suppress T-cell proliferation in a dose-dependent manner similar to their bone marrow-derived counterparts. Also similar to bone marrow-derived MSCs, prostate cancer-infiltrating MSCs upregulate expression of PD-L1 and PD-L2 on their cell surface in the presence of IFNγ and TNFα. Prostate cancer-infiltrating MSCs suppress T-cell proliferation similar to canonical bone marrow-derived MSCs, which have well-documented immunosuppressive properties with numerous effects on both innate and adaptive immune system function. Thus, we hypothesize that selective depletion of MSCs infiltrating sites of prostate cancer should restore immunologic recognition and elimination of malignant cells via broad re-activation of cytotoxic pro-inflammatory pathways.
Sections du résumé
BACKGROUND
Prostate cancer is characterized by T-cell exclusion, which is consistent with their poor responses to immunotherapy. In addition, T-cells restricted to the adjacent stroma and benign areas are characterized by anergic and immunosuppressive phenotypes. In order for immunotherapies to produce robust anti-tumor responses in prostate cancer, this exclusion barrier and immunosuppressive microenvironment must first be overcome. We have previously identified mesenchymal stem cells (MSCs) in primary and metastatic human prostate cancer tissue.
METHODS
An Opal Multiplex immunofluorescence assay based on CD73, CD90, and CD105 staining was used to identify triple-labeled MSCs in human prostate cancer tissue. T-cell suppression assays and flow cytometry were used to demonstrate the immunosuppressive potential of primary MSCs expanded from human bone marrow and prostate cancer tissue from independent donors.
RESULTS
Endogenous MSCs were confirmed to be present at sites of human prostate cancer. These prostate cancer-infiltrating MSCs suppress T-cell proliferation in a dose-dependent manner similar to their bone marrow-derived counterparts. Also similar to bone marrow-derived MSCs, prostate cancer-infiltrating MSCs upregulate expression of PD-L1 and PD-L2 on their cell surface in the presence of IFNγ and TNFα.
CONCLUSION
Prostate cancer-infiltrating MSCs suppress T-cell proliferation similar to canonical bone marrow-derived MSCs, which have well-documented immunosuppressive properties with numerous effects on both innate and adaptive immune system function. Thus, we hypothesize that selective depletion of MSCs infiltrating sites of prostate cancer should restore immunologic recognition and elimination of malignant cells via broad re-activation of cytotoxic pro-inflammatory pathways.
Identifiants
pubmed: 30488530
doi: 10.1002/pros.23738
pmc: PMC6549513
mid: NIHMS1032144
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
320-330Subventions
Organisme : NCI NIH HHS
ID : R01CA201035
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201035
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA058236
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NIH HHS
ID : P30 CA058236
Pays : United States
Informations de copyright
© 2018 Wiley Periodicals, Inc.
Références
Endocr Relat Cancer. 2013 Aug 23;20(5):R269-90
pubmed: 23975882
Curr Opin Immunol. 2016 Apr;39:1-6
pubmed: 26609943
Cancers (Basel). 2012 Feb 22;4(1):193-217
pubmed: 24213236
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
Prostate. 2015 Jun;75(8):806-14
pubmed: 25663042
Mol Cancer Ther. 2012 Feb;11(2):257-66
pubmed: 22323494
Gene Ther. 2008 May;15(10):730-8
pubmed: 18401438
Nat Rev Cancer. 2007 Apr;7(4):256-69
pubmed: 17384581
Clin Exp Immunol. 2009 Apr;156(1):149-60
pubmed: 19210524
Stem Cell Reports. 2013 Jul 25;1(2):139-51
pubmed: 24052949
Immunity. 2018 Jun 19;48(6):1077-1080
pubmed: 29924973
Cancer Metastasis Rev. 2010 Jun;29(2):249-61
pubmed: 20411303
Cell Death Differ. 2014 Mar;21(3):388-96
pubmed: 24162664
N Engl J Med. 2005 Sep 22;353(12):1224-35
pubmed: 16177248
Prostate. 2007 Dec 1;67(16):1729-39
pubmed: 17879963
BMC Cancer. 2013 May 25;13:258
pubmed: 23705594
J Natl Cancer Inst. 2013 Jul 17;105(14):1050-8
pubmed: 23847245
Stem Cells. 2011 Jan;29(1):11-9
pubmed: 21280155
Cell Stem Cell. 2011 Jul 8;9(1):11-5
pubmed: 21726829
J Exp Med. 2013 Jun 3;210(6):1137-51
pubmed: 23712428
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Oncoimmunology. 2015 Apr 1;4(7):e1016700
pubmed: 26140242
Prostate. 2009 Nov 1;69(15):1694-703
pubmed: 19670224
Clin Exp Allergy. 2011 Apr;41(4):526-34
pubmed: 21255158
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Cancer Metastasis Rev. 2014 Sep;33(2-3):641-55
pubmed: 24477411
Biochem Biophys Res Commun. 2007 May 11;356(3):780-4
pubmed: 17382293
PLoS One. 2010 Sep 23;5(9):e12920
pubmed: 20886110
Stem Cells. 2017 Apr;35(4):851-858
pubmed: 28294454
J Immunol. 2014 Feb 15;192(4):1491-501
pubmed: 24403533
Clin Cancer Res. 2008 Jun 1;14(11):3254-61
pubmed: 18519750
J Leukoc Biol. 2017 Aug;102(2):393-406
pubmed: 28550116
Transfus Med Rev. 2016 Jan;30(1):37-43
pubmed: 26689863
Prostate. 2016 May;76(6):552-64
pubmed: 26732992
J Cell Biochem. 2011 Aug;112(8):1963-8
pubmed: 21445861
Cell Stem Cell. 2012 Mar 2;10(3):244-58
pubmed: 22385653
Am J Pathol. 2018 Jun;188(6):1478-1485
pubmed: 29577933
Front Physiol. 2016 Feb 09;7:24
pubmed: 26903875
Prostate. 2001 May 15;47(3):222-9
pubmed: 11351352
J Exp Med. 2011 Sep 26;208(10):1949-62
pubmed: 21930770
Cancer Res. 2008 Jun 1;68(11):4331-9
pubmed: 18519693
Clin Cancer Res. 1995 May;1(5):473-80
pubmed: 9816006
PLoS One. 2008 Jun 25;3(6):e2563
pubmed: 18575622
Curr Opin Urol. 2017 Nov;27(6):566-571
pubmed: 28825923
Blood. 2008 Feb 1;111(3):1327-33
pubmed: 17951526
Histopathology. 2012 Jan;60(1):199-215
pubmed: 22212087
Stem Cells. 2007 Jul;25(7):1737-45
pubmed: 17395768
Stem Cells Transl Med. 2018 Sep;7(9):651-663
pubmed: 30070053
Transplantation. 2003 Oct 27;76(8):1208-13
pubmed: 14578755
Oncotarget. 2017 Jul 18;8(29):46710-46727
pubmed: 28493842
Oncotarget. 2016 Nov 1;7(44):71298-71308
pubmed: 27542256
Expert Rev Clin Pharmacol. 2018 May;11(5):475-486
pubmed: 29641940
J Immunol. 2013 May 15;190(10):5065-77
pubmed: 23589610
Prostate. 1997 Dec 1;33(4):233-9
pubmed: 9397194
Stem Cells. 2012 Nov;30(11):2498-511
pubmed: 22911900
Urology. 2001 Apr;57(4 Suppl 1):115-20
pubmed: 11295607
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Oncotarget. 2016 Dec 27;7(52):85764-85775
pubmed: 26967390
Histol Histopathol. 2011 Jul;26(7):941-51
pubmed: 21630223
Cell Stem Cell. 2008 Sep 11;3(3):301-13
pubmed: 18786417
Clin Cancer Res. 2017 Nov 15;23(22):6764-6770
pubmed: 28663235
Eur J Immunol. 2005 May;35(5):1482-90
pubmed: 15827960
Nat Biotechnol. 2014 Mar;32(3):252-60
pubmed: 24561556
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Mol Biol Cell. 2002 Dec;13(12):4279-95
pubmed: 12475952
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Blood. 2006 Jan 1;107(1):367-72
pubmed: 16141348
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
Nature. 2011 Feb 10;470(7333):214-20
pubmed: 21307934
Stem Cells. 2013 Oct;31(10):2042-6
pubmed: 23681848
Mol Ther. 2012 Jan;20(1):14-20
pubmed: 22008910
Stem Cells. 2007 Aug;25(8):2025-32
pubmed: 17510220
Biomed Res Int. 2014;2014:216806
pubmed: 25025040
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
J Cell Mol Med. 2011 Mar;15(3):635-46
pubmed: 20184663
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70
pubmed: 11734652
Nat Commun. 2014 Sep 25;5:4988
pubmed: 25255306
Nat Rev Drug Discov. 2017 Jan;16(1):35-52
pubmed: 27811929
Microvasc Res. 2003 Sep;66(2):102-12
pubmed: 12935768
Science. 2010 Nov 5;330(6005):827-30
pubmed: 21051638
Cell Stem Cell. 2012 Dec 7;11(6):812-24
pubmed: 23168163
Tissue Eng. 2006 Oct;12(10):2875-88
pubmed: 17518656
Stem Cells Transl Med. 2017 Feb;6(2):394-404
pubmed: 28191756
Nat Rev Immunol. 2010 Aug;10(8):580-93
pubmed: 20651745
Stem Cells. 2017 Mar;35(3):766-776
pubmed: 27671847
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
J Immunol Methods. 2009 Aug 31;348(1-2):9-17
pubmed: 19552894
Curr Opin Urol. 2016 Nov;26(6):529-34
pubmed: 27533500
J Immunother Cancer. 2017 Apr 18;5:31
pubmed: 28428880
J Cell Physiol. 2008 Mar;214(3):588-94
pubmed: 17786951
Oncotarget. 2013 Jan;4(1):106-17
pubmed: 23362217
Stem Cells. 2009 Aug;27(8):1954-62
pubmed: 19544427
Int J Cancer. 2016 Jan 15;138(2):417-27
pubmed: 26235173
Nat Commun. 2013;4:1795
pubmed: 23653207
J Clin Invest. 2011 Apr;121(4):1298-312
pubmed: 21436587
Eur J Cancer. 2009 Jun;45(9):1664-72
pubmed: 19318244
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32
pubmed: 26260996
Cell Stem Cell. 2018 Jun 01;22(6):824-833
pubmed: 29859173
Am J Pathol. 1999 Dec;155(6):1985-92
pubmed: 10595928
Leukemia. 2011 Apr;25(4):648-54
pubmed: 21242993
J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13
pubmed: 16684817
Stem Cells Int. 2016;2016:1314709
pubmed: 26880933
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16389-94
pubmed: 25313057
Immunol Lett. 2015 Dec;168(2):136-9
pubmed: 26079607
Biomaterials. 2016 Jun;91:140-150
pubmed: 27019026
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
Front Immunol. 2013 Sep 04;4:201
pubmed: 24027567